Bevacizumab and granulocyte-macrophage colony-stimulating factor in pretreated patients with metastatic solid malignancies

Bevacizumab (BEV) is an important anti-angiogenetic agent which may also stimulate the generation of dendritic cells (DC). This effect may be further potentiated by GM-CSF. This trial was initiated to study BEV+GM-CSF in 21 patients (pts) with metastatic solid malignancies: ovarian cancer, n=8; breast cancer, n=5; primary peritoneal carcinoma, n=3; hormone-refractory prostate cancer, n=2; others, n=3. All pts have been considered refractory to chemotherapy or non-treatable due to their baseline bone marrow and/or organ functions. Eight patients had previously received BEV as part of other anti-neoplastic regimen…